Back

Serious adverse events, hospitalization, and mortality associated with icosapent ethyl: a pharmacovigilance analysis using the FDA adverse event reporting system

29 August 2026 (11:15 - 11:40)
Organised by: Logo
Congress Presentation Part of: Emerging perspectives in cardiovascular care: prevention, policy, and practice Public Health ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Alexandru-Ioan Draghici

Cluj-Napoca (Romania)

3 More presentations in this session

Presentation thumbnail
Value-based cardiovascular care in Ukraine: transitioning from generic monotherapy to branded fixed-dose combinations (FDCs) and pharmaceutical support
Assistant Professor N. Bilousova (Kiev, UA)
Abstract Slides Video
Presentation thumbnail
Cardiovascular disease prevention policy in the four nations of the United Kingdom: a policy document analysis from 2000-2025
Doctor I. Lyell (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Economic evaluation of Impella versus VA-ECMO in acute myocardial infarction cardiogenic shock
Doctor R. Batchelor (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging perspectives in cardiovascular care: prevention, policy, and practice

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
30 August 2025
thumbnail
Congress Presentation
Decreased risk of cardiovascular events in patients with atrial fibrillation treated with lipid-lowering therapy: 2-year follow-up of the Global ETNA-AF program
30 August 2025
thumbnail
Congress Presentation
Cardiovascular outcomes and mortality associated with proton pump inhibitors versus histamine-2 receptor antagonists in patients with heart failure: a target trial emulation study
28 August 2026
thumbnail
Congress Presentation
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources